Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2017 | PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. | Jiao, S; Xia, W; Yamaguchi, H; Wei, Y; Chen, MK; Hsu, JM; Hsu, JL; Yu, WH; Du, Y; Lee, HH; Li, CW ; Chou, CK; Lim, SO; Chang, SS; Litton, J; Arun, B; Hortobagyi, GN; Hung, MC | Clinical cancer research : an official journal of the American Association for Cancer Research 23(14), 3711-3720 | |||
2019 | Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. | Han, Y; Chen, MK; Wang, HL; Hsu, JL; Li, CW ; Chu, YY; Liu, CX; Nie, L; Chan, LC; Yam, C; Wang, SC; He, GJ; Hortobagyi, GN; Tan, XD; Hung, MC | American journal of cancer research 9(3), 608-618 |